NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF

Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellular signaling region consists of a co-stimulatory domain, a primary signal transduction domain, and a γC chain or intracellular region thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 14. März Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

ZHOU YALI [VerfasserIn]
CHEN GONG [VerfasserIn]
GUO TINGTING [VerfasserIn]
JIANG XIAOYAN [VerfasserIn]
REN JIANGTAO [VerfasserIn]
HE XIAOHONG [VerfasserIn]
WANG YANBIN [VerfasserIn]
HAN LU [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
bio
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-03-14, Last update posted on www.tib.eu: 2024-04-03, Last updated: 2024-04-09

Patentnummer:

US2024082306

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA00256114X